Teriparatide
Also known as: Bonsity, Forsteo, Forteo, LY333334, Movymia, rhPTH(1-34), Teriparatide acetate, TPD
Source Teriparatide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Recombinant human parathyroid hormone (1-34) fragment administered subcutaneously to treat osteoporosis and increase bone mineral density.
Mechanism of Action
Selective agonist of PTH1 receptor; intermittent activation stimulates osteoblast activity and bone formation
Routes of Administration
Goals & Uses
- Treatment of male osteoporosisBone HealthModerate
- Treatment of glucocorticoid-induced osteoporosisBone HealthHigh
- Osteoporosis treatmentBone MetabolismHigh
- Increase in bone mineral densityBone HealthHigh
- Reduction of vertebral fracture riskBone HealthHigh
- Increase BMDBone HealthHigh
- Reduction of nonvertebral fracture riskBone HealthHigh
- Fracture healingBone RepairLow
Contraindications
- Prior skeletal radiation therapyOncologyModerate
- Bone metastasesOncologyHigh
- Prior radiation therapy involving the skeletonOncologicHigh
- HypercalcemiaMetabolic DisorderHigh
- Severe renal impairmentOrganModerateKidney function concerns
- Pediatric patients with open epiphysesPediatricHigh
- Paget's disease of boneBone DisorderHigh
- Osteosarcoma or prior skeletal malignancyOncologicHigh
- Paget disease of boneSkeletalModerate
Adverse Effects
- Dizziness/orthostatic hypotensionCardiovascularCommon
- HypercalcemiaMetabolicUncommon
- Injection site reactionsLocalCommon
- HypercalciuriaMetabolicCommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Leg crampsMusculoskeletalCommon
- DizzinessNeurologicCommonFeeling faint, lightheaded, or unsteady
Drug Interactions
- Loop diureticsModerate
- Calcium/vitamin D supplementsModerate
- BisphosphonatesLow
- DigoxinHigh
- Calcium supplements and vitamin DLow
- Antiresorptive agents (bisphosphonates)Moderate
- Thiazide diureticsModerate
Population Constraints
- PregnancyReproductive SafetyAbsolute
- Patients with prior osteosarcomaOncologicAbsolute
- Pediatric patientsAgeAbsolute
- Patients with active urolithiasisUrologicRelative
- Pregnant womenReproductiveAbsolute
- Severe renal impairment (CrCl <30 mL/min)Organ ImpairmentRelative
- Children <18 yearsAgeRelative
Regulatory Status
- European UnionApprovedApproved: severe osteoporosisSame duration limit
- United StatesApprovedApproved: postmenopausal osteoporosis, male osteoporosisLimited to 2 years of cumulative use
- United KingdomApprovedApproved: osteoporosis
FDA approved 2002 (brand Forteo); EMA approved for severe osteoporosis; marketed as teriparatide acetate.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Teriparatide?
Recombinant human parathyroid hormone (1-34) fragment administered subcutaneously to treat osteoporosis and increase bone mineral density.
What is Teriparatide used for?
Teriparatide is educationally associated with: Treatment of male osteoporosis, Treatment of glucocorticoid-induced osteoporosis, Osteoporosis treatment, Increase in bone mineral density, Reduction of vertebral fracture risk, Increase BMD, Reduction of nonvertebral fracture risk, Fracture healing. Educational only — not medical advice.
How is Teriparatide administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Teriparatide?
Reported adverse effects include: Dizziness/orthostatic hypotension, Hypercalcemia, Injection site reactions, Hypercalciuria, Nausea, Leg cramps, Dizziness. This list is not exhaustive — consult a qualified clinician.
Who should avoid Teriparatide?
Recorded contraindications: Prior skeletal radiation therapy, Bone metastases, Prior radiation therapy involving the skeleton, Hypercalcemia, Severe renal impairment, Pediatric patients with open epiphyses, Paget's disease of bone, Osteosarcoma or prior skeletal malignancy, Paget disease of bone. Consult a qualified clinician before use.